Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 10Phase NA 3Phase 4 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 4Multiple Myeloma 3Melanoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligometastatic Disease 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Arsenic Trioxide 2Tretinoin 1Tacrolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Homoharringtonine 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Drug Therapy 1Cytarabine 1Cyclophosphamide 1Clofarabine 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Promyelocytic, Acute × Tretinoin × Clear all
NCT05497310 2022-10-26

Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL

Hospital Universitario Dr. Jose E. Gonzalez

Phase 1/2 Unknown
15 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡